No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.
about
Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysisInvestigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patients
P2860
No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
No evidence for association of ...... with prostate cancer outcomes.
@en
No evidence for association of ...... with prostate cancer outcomes.
@nl
type
label
No evidence for association of ...... with prostate cancer outcomes.
@en
No evidence for association of ...... with prostate cancer outcomes.
@nl
prefLabel
No evidence for association of ...... with prostate cancer outcomes.
@en
No evidence for association of ...... with prostate cancer outcomes.
@nl
P2093
P2860
P1433
P1476
No evidence for association of ...... with prostate cancer outcomes.
@en
P2093
Calvin Cooper
Carmen A Perez
Chuanzhong Ye
Heidi Chen
Jerry J Jaboin
Marcia L Wills
Misun Hwang
P2860
P304
P356
10.1016/J.UROLONC.2009.03.031
P50
P577
2009-06-12T00:00:00Z